Begum Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Begum Yilmaz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdulmunir Azizy
Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey
1 shared publication - Ayca Iribas Celik
Department of Radiation Oncology, Institute of Oncology, Istanbul University, 34093 Fatih, Istanbul, Türkiye
1 shared publication - Can Ilgin
Department of Radiation Oncology, Institute of Oncology, Istanbul University, 34093 Fatih, Istanbul, Türkiye
1 shared publication - Canan Koksal
Department of Medical Physics, Institute of Oncology, Istanbul University, 34093 Istanbul, Türkiye
1 shared publication - Deniz Bolukbas
Department of Radiation Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Türkiye
1 shared publication - Inci Kizildag Yirgin
Department of Radiology, Institute of Oncology, Istanbul University, 34093 Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 25 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2142
Prognostic Significance of Nomogram and T-Score in Locally Advanced Cervical Cancer Patients Treated with Curative Chemoradiotherapy and Image-Guided Brachytherapy: A Single-Center Retrospective Study
Objective: To investigate the survival prediction probability of the nomogram from retro-EMBRACE and the T-score in patients with locally advanced cervical cancer (LACC). Materials and Methods: A total of 204 patients with LACC who underwent curative chemoradiotherapy and brachytherapy (BT) between 2010 and 2021 were included in our single-center retrospective study. Clinical records, examinations, and magnetic resonance images (MRI) before and after external beam radiotherapy (EBRT) were retrospectively reviewed to obtain information on age, tumor size, parametrial involvement, ureteral involvement, bladder invasion, uterine involvement, high-risk clinical target volume at the first brachytherapy application, lymph node involvement, vaginal involvement, recurrence, metastasis, and last follow-up. The 5-year overall survival probabilities of the patients were determined by nomogram. T-score was calculated separately at diagnosis (TSD) and brachytherapy (TSBT), and their effects on local recurrence-free survival, disease-free survival, and overall survival were analyzed. Results: The median age was 52 (29–89). The 5-year survival rate of the patients was calculated to be 90.18%. The median nomogram’s survival estimate for 60 months was 70.35% (20.9–87.1). The median TSD and TSBT were 5.5 (1–16) and 1 (0–6), respectively. According to the multivariate Cox regression models, TSD (HR = 1.203, 95% CI 1.021–1.417, p = 0.024) was significantly associated with local recurrence-free survival. Conclusions: This study demonstrated that the nomogram’s predictions for 60-month overall survival are underestimates. Prognosis can be estimated using the TSD, which can be easily obtained with a clinical examination and detailed MRI examination.
- 25 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2142
Open AccessPrognostic Significance of Nomogram and T-Score in Locally Advanced Cervical Cancer Patients Treated with Curative Chemoradiotherapy and Image-Guided Brachytherapy: A Single-Center Retrospective Study
Objective: To investigate the survival prediction probability of the nomogram from retro-EMBRACE and the T-score in patients with locally advanced cervical cancer (LACC). Materials and Methods: A total of 204 patients with LACC who underwent curative chemoradiotherapy and brachytherapy (BT) between 2010 and 2021 were included in our single-center retrospective study. Clinical records, examinations, and magnetic resonance images (MRI) before and after external beam radiotherapy (EBRT) were retrospectively reviewed to obtain information on age, tumor size, parametrial involvement, ureteral involvement, bladder invasion, uterine involvement, high-risk clinical target volume at the first brachytherapy application, lymph node involvement, vaginal involvement, recurrence, metastasis, and last follow-up. The 5-year overall survival probabilities of the patients were determined by nomogram. T-score was calculated separately at diagnosis (TSD) and brachytherapy (TSBT), and their effects on local recurrence-free survival, disease-free survival, and overall survival were analyzed. Results: The median age was 52 (29–89). The 5-year survival rate of the patients was calculated to be 90.18%. The median nomogram’s survival estimate for 60 months was 70.35% (20.9–87.1). The median TSD and TSBT were 5.5 (1–16) and 1 (0–6), respectively. According to the multivariate Cox regression models, TSD (HR = 1.203, 95% CI 1.021–1.417, p = 0.024) was significantly associated with local recurrence-free survival. Conclusions: This study demonstrated that the nomogram’s predictions for 60-month overall survival are underestimates. Prognosis can be estimated using the TSD, which can be easily obtained with a clinical examination and detailed MRI examination.